Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia
| Authors | |
|---|---|
| Year of publication | 2013 |
| Type | Article in Periodical |
| Magazine / Source | Genomics |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1016/j.ygeno.2013.06.007 |
| Field | Oncology and hematology |
| Keywords | Multiple myeloma; Plasma cell leukemia; Cell cycle genes; Overall survival; Time-to-progression |
| Description | The objective of this study was to describe co-expression correlations of cell cycle regulatory genes in multiple myeloma (MM) and plasma cell leukemia (PCL). Our results highlight the presence of dynamic equilibrium between co-expression of activator and inhibitor gene sets. Moreover inhibitor set is more sensitive to the activator changes, not vice versa. We have shown that CDKN2A expression is associated with short-term survival in newly diagnosed MM patients (survival was 30.3 +/- 3.9 months for 'low' expressed and 7.5 +/- 5.6 months for 'high' expressed group, p < 0.0001). Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission was 20.8 +/- 3.6 months for 'low' and 8.4 +/- 2.7 months for 'high' expressed group, p < 0.0001) as well as in whole studied cohort of MM patients (remission was 20.8 +/- 2.8 months for 'low' and 9.8 +/- 1.1 months for 'high' expressed group, p < 0.0001). The overexpression of inhibitors can be explained as a compensatory reaction to growing "oncogenic stress". |
| Related projects: |
|